Mayumi Fujita, MD, PhD
Professor, Dermatology

Photo
Medical School:
  • MD, Kyoto University - Kyoto, Japan (1983)
Graduate School :
  • PhD, Kyoto University (1992)
Internships:
  • University of Washington Program (1999)
  • Kyoto University Program (1983)
Residencies:
  • University of Washington Program, Dermatology (2002)
  • Kyoto University Program, Dermatology (1987)
Fellowships:
  • University of Colorado (University Hospital) Program, Dermatology (1996)
Languages: English, Japanese
Department: Dermatology

Research Interests

Dr. Fujita is a tenured professor of Dermatology and Immunology & Microbiology, and a dermatologist at the Univ. of Colorado School of Medicine and VA Eastern Colorado Healthcare System, as well as a Director of Research Services, Dermatology RC-1S. The Fujita Lab studies biological roles and molecular regulations of 1) IL-1b, inflammasomes and autoinflammation in human melanoma, 2) IL-37 in adaptive immunity, 3) tumor heterogeneity in melanoma and its therapeutic resistance, and 4) damages to melanocytes and keratinocytes. The Lab is currently funded by NIH/NCI R01 (as a PI), VA Merit Awards (one as a PI and the other two as a co-I), and the Cancer League of Colorado (as a PI), and Dr. Fujita produced 98 peer-reviewed publications (https://www.ncbi.nlm.nih.gov/myncbi/mayumi.fujita.1/bibliography/public/).

Publications

  • Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020;10(14):6261-6277. doi: 10.7150/thno.42523. eCollection 2020. Review. PubMed PMID: 32483452
  • Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443. doi: 10.1038/s41419-020-2646-2. PubMed PMID: 32513939
  • Anwar A, Anwar H, Yamauchi T, Tseng R, Agarwal R, Horwitz LD, Zhai Z, Fujita M. Bucillamine Inhibits UVB-Induced MAPK Activation and Apoptosis in Human HaCaT Keratinocytes and SKH-1 Hairless Mouse Skin. Photochem Photobiol. 2020 Jul;96(4):870-876. doi: 10.1111/php.13228. Epub 2020 Apr 13. PubMed PMID: 32077107
  • Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020 Aug 5;12(8). doi: 10.3390/cancers12082182. PubMed PMID: 32764384
  • Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. MELANOCYTE PRECURSORS IN THE HAIR FOLLICLE BULGE OF REPIGMENTED VITILIGO SKIN ARE CONTROLLED BY RHO-GTPase, KCTD10 AND CTNNB1 SIGNALING. J Invest Dermatol. 2020 Aug 12;. doi: 10.1016/j.jid.2020.07.016. [Epub ahead of print] PubMed PMID: 32800877
  • Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, Ravindran Menon D, Fujita M: Inflammasome sensor NLRP1 confers acquired drug resistance to temozolomide in human melanoma. Cancers 2020 Sep 4;12(9). doi: 10.3390/cancers12092518. PubMed PMID: 32899791.
  • Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF. Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. J Invest Dermatol. 2020 Feb;140(2):269-274. PubMed PMID: 31348921
  • Anwar A, Anwar H, Yamauchi T, Tseng R, Agarwal R, Horwitz LD, Zhai Z, Fujita M. Bucillamine Inhibits UVB-Induced MAPK Activation and Apoptosis in Human HaCaT Keratinocytes and SKH-1 Hairless Mouse Skin. Photochem Photobiol. 2020 Jul;96(4):870-876. PubMed PMID: 32077107
  • Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020;10(14):6261-6277. PubMed PMID: 32483452
  • Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443. PubMed PMID: 32513939
  • Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020 Aug 5;12(8). PubMed PMID: 32764384
  • Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, Ravindran Menon D, Fujita M. Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers (Basel). 2020 Sep 4;12(9). PubMed PMID: 32899791
  • de Graaf DM, Jaeger M, van den Munckhof ICL, Ter Horst R, Schraa K, Zwaag J, Kox M, Fujita M, Yamauchi T, Mercurio L, Madonna S, Rutten JHW, de Graaf J, Riksen NP, van de Veerdonk FL, Netea MG, Joosten LAB, Dinarello CA. Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. Eur J Immunol. 2020 Oct 30. [Epub ahead of print] PubMed PMID: 33125159
  • Samson JM, Ravindran Menon D, Vaddi PK, Kalani Williams N, Domenico J, Zhai Z, Backos DS, Fujita M. Computational Modeling of NLRP3 Identifies Enhanced ATP Binding and Multimerization in Cryopyrin-Associated Periodic Syndromes. Front Immunol. 2020;11:584364. PubMed PMID: 33329557
  • Maghfour J, Rietcheck HR, Rundle CW, Runion TM, Jafri ZA, Dercon S, Lio P, Fernandez J, Fujita M, Dellavalle RP, Yardley H. An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin. J Drugs Dermatol. 2020 Dec 1;19(12):1204-1208. PubMed PMID: 33346512
  • Zhai Z, Vaddi PK, Samson JM, Takegami T, Fujita M. NLRP1 Functions Downstream of the MAPK/ERK Signaling via ATF4 and Contributes to Acquired Targeted Therapy Resistance in Human Metastatic Melanoma. Pharmaceuticals (Basel). 2020 Dec 30;14(1). PubMed PMID: 33396632
  • Matsumoto A, Ito S, Wakamatsu K, Ichiba M, Vasiliou V, Akao C, Song BJ, Fujita M. Ethanol induces skin hyperpigmentation in mice with aldehyde dehydrogenase 2 deficiency. Chem Biol Interact. 2019 Apr 1;302:61-66. PubMed PMID: 30721697
  • Menon DR, Fujita M. A state of stochastic cancer stemness through the CDK1-SOX2 axis. Oncotarget. 2019 Apr 5;10(27):2583-2585. PubMed PMID: 31080551
  • Osborne DG, Domenico J, Luo Y, Reid AL, Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA, Fujita M. Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Mol Carcinog. 2019 Sep;58(9):1670-1679. PubMed PMID: 31099111
  • Samson JM, Ravindran Menon D, Smith DE, Baird E, Kitano T, Gao D, Tan AC, Fujita M. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Chem Biol Interact. 2019 Dec 1;314:108822. PubMed PMID: 31580832
  • Kuprys PV, Tsukamoto H, Gao B, Jia L, McGowan J, Coopersmith CM, Moreno MC, Hulsebus H, Meena AS, Souza-Smith FM, Roper P, Foster MT, Raju SV, Marshall SA, Fujita M, Curtis BJ, Wyatt TA, Mandrekar P, Kovacs EJ, Choudhry MA. Summary of the 2018 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2019 Jun;77:11-18. PubMed PMID: 30763905
  • Leachman SA, Hornyak TJ, Barsh G, Bastian BC, Brash DE, Cleaver JE, Cooper CD, D'Orazio JA, Fujita M, Holmen SL, Indra AK, Kraemer KH, Le Poole IC, Lo RS, Lund AW, Manga P, Pavan WJ, Setaluri V, Stemwedel CE, Kulesz-Martin MF. Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. J Invest Dermatol. 2019 Jul 23. [Epub ahead of print] PubMed PMID: 31348921
  • Højen JF, Kristensen MLV, McKee AS, Wade MT, Azam T, Lunding LP, de Graaf DM, Swartzwelter BJ, Wegmann M, Tolstrup M, Beckman K, Fujita M, Fischer S, Dinarello CA. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 Sep;20(9):1138-1149. PubMed PMID: 31427775
  • Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the ß-Catenin Pathway in the Hair Follicle Bulge Stem Cells. J Invest Dermatol. 2018 Mar;138(3):657-668. PubMed PMID: 29054607
  • Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the ß-Catenin Pathway in the Hair Follicle Bulge Stem Cells. J Invest Dermatol. 2018 Mar;138(3):657-668. PubMed PMID: 29054607
  • Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M. CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. Cancer Res. 2018 Dec 1;78(23):6561-6574. PubMed PMID: 30297536
  • Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A, Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE. ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH(High) Melanoma-Initiating Cells. Cell Chem Biol. 2018 Dec 20;25(12):1456-1469.e6. PubMed PMID: 30293938
  • Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF. Frontiers in pigment cell and melanoma research. Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. PubMed PMID: 30281213
  • Armstrong AW, Chambers CJ, Maverakis E, Cheng MY, Dunnick CA, Chren MM, Gelfand JM, Wong DJ, Gibbons BM, Gibbons CM, Torres J, Steel AC, Wang EA, Clark CM, Singh S, Kornmehl HA, Wilken R, Florek AG, Ford AR, Ma C, Ehsani-Chimeh N, Boddu S, Fujita M, Young PM, Rivas-Sanchez C, Cornejo BI, Serna LC, Carlson ER, Lane CJ. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open. 2018 Oct 5;1(6):e183062. PubMed PMID: 30646223
  • Kuprys PV, Tsukamoto H, Gao B, Jia L, McGowan J, Coopersmith CM, Moreno MC, Hulsebus H, Meena AS, Souza-Smith FM, Roper P, Foster MT, Raju SV, Marshall SA, Fujita M, Curtis BJ, Wyatt TA, Mandrekar P, Kovacs EJ, Choudhry MA. Summary of the 2018 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2018 Aug 24;77:11-18. [Epub ahead of print] PubMed PMID: 30763905
  • Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18;8(29):46801-46817. PubMed PMID: 27086916
  • Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, Fujita M. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 2017 Jul 6;36(27):3820-3830. PubMed PMID: 28263976
  • Li Y, Fujita M, Boraschi D. Endotoxin Contamination in Nanomaterials Leads to the Misinterpretation of Immunosafety Results. Front Immunol. 2017;8:472. PubMed PMID: 28533772
  • Pearson DR, Fujita M, High WA. Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course. J Mol Biomark Diagn. 2017 May;8(3). PubMed PMID: 28758048
  • Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, O'Connell RM. microRNAs in Psoriasis. J Invest Dermatol. 2016 Feb;136(2):365-71. PubMed PMID: 26802234
  • Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2016 Apr 12. [Epub ahead of print] PubMed PMID: 27086916
  • Dinarello CA, Nold-Petry C, Nold M, Fujita M, Li S, Kim S, Bufler P. Suppression of innate inflammation and immunity by interleukin-37. Eur J Immunol. 2016 May;46(5):1067-81. PubMed PMID: 27060871
  • Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget. 2016 Dec 20;7(51):84594-84607. PubMed PMID: 27829238
  • Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells. J Invest Dermatol. 2015 Mar;135(3):842-50. PubMed PMID: 25350317
  • Snedecor ER, Sung CC, Moncayo A, Rothstein BE, Mockler DC, Tonnesen MG, Jones EC, Fujita M, Clark RA, Shroyer KR, Chen J. Loss of Primary Cilia in Melanoma Cells Is Likely Independent of Proliferation and Cell Cycle Progression. J Invest Dermatol. 2015 Jan 28. [Epub ahead of print] PubMed PMID: 25629424
  • Chen HM, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015 Mar;72(1):113-4. PubMed PMID: 25592113
  • Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, Kim S, Dinarello CA. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2497-502. PubMed PMID: 25654981
  • Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar;135(3):842-50. PubMed PMID: 25350317
  • Snedecor ER, Sung CC, Moncayo A, Rothstein BE, Mockler DC, Tonnesen MG, Jones EC, Fujita M, Clark RA, Shroyer KR, Chen J. Loss of primary cilia in melanoma cells is likely independent of proliferation and cell cycle progression. J Invest Dermatol. 2015 May;135(5):1456-8. PubMed PMID: 25629424
  • Nguyen N, Couts KL, Luo Y, Fujita M. Understanding melanoma stem cells. Melanoma Manag. 2015;2(2):179-188. PubMed PMID: 26594315
  • Mukherjee N, Schwan JV, Fujita M, Norris DA, Shellman YG. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. J Invest Dermatol. 2015 Sep;135(9):2155-61. PubMed PMID: 25947358
  • Højen JF, Rasmussen TA, Andersen KL, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS, Dinarello CA, Tolstrup M. Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. Mol Med. 2015 Apr 14;21:337-45. PubMed PMID: 25879630
  • Singh SP, Schwartz MP, Tokuda EY, Luo Y, Rogers RE, Fujita M, Ahn NG, Anseth KS. A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression. Sci Rep. 2015 Dec 7;5:17814. PubMed PMID: 26638791
View All (48 Total) View Less

Practice Locations

UCH - Dermatology Clinic
1665 Aurora Ct
3rd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0500

Rocky Mountain Regional Veterans Administration Medical Center
1700 Wheeling St
Aurora, CO 80045
303-399-8020

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

Specialties
  • Dermatology, Board Certification (2002)
Clinical Interests
I am interested in Psoriasis and Adult Dermatology.

General Information

Medical Schools:
  • MD, Kyoto University - Kyoto, Japan (1983)
Graduate Schools:
  • PhD, Kyoto University (1992)
Internships:
  • University of Washington Program (1999)
  • Kyoto University Program (1983)
Residency Programs:
  • University of Washington Program, Dermatology (2002)
  • Kyoto University Program, Dermatology (1987)
Fellowships:
  • University of Colorado (University Hospital) Program, Dermatology (1996)
Languages: English, Japanese
Department: Dermatology
;